FDA Clears Merck’s Oral PCSK9 Inhibitor Lipfendra for Ultra‑Low LDL Cholesterol Targets

The Food and Drug Administration gave its approval on Thursday to a new daily oral medication that can drive cholesterol levels well below those attainable with existing statins.

Manufactured by Merck under the brand name Lipfendra (enclitide is its generic name), the therapy can reduce low‑density lipoprotein (LDL) — the harmful cholesterol fraction — into the 50‑60 mg/dL range or lower. Typical untreated adults have LDL levels above 100 mg/dL. The mechanism of action is inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9).

Guidelines from the American Heart Association and the American College of Cardiology recommend LDL targets of <70 mg/dL for individuals at elevated cardiovascular risk and <55 mg/dL for those who have already experienced a heart attack or are otherwise very high‑risk.

Merck’s list price for Lipfendra will be $315 for a 30‑day supply, and the medication is expected to reach pharmacies within a few weeks, according to spokeswoman Julia Cunningham.

Comparable injectable PCSK9 inhibitors already exist, but they carry list prices of $500‑$600 per month or higher, leading insurers to be hesitant and many patients to avoid injections. Currently only about 1 % of the roughly six million U.S. patients who could benefit are using those injectables. Clinical data, however, show that PCSK9 inhibition can cut heart‑attack risk by roughly 20 % in high‑risk individuals.

Independent cardiologists welcomed both the FDA’s decision and Lipfendra’s pricing, expressing optimism that an oral alternative that is less costly than injectables will improve adherence and enable far more at‑risk patients to achieve therapeutic LDL goals.

“I’m thrilled,” said Dr. Christopher Cannon, a cardiologist at Brigham and Women’s Hospital in Boston who provides consulting for several pharmaceutical companies, though not for Merck.

“This would make a big difference compared with the cost of injectable PCSK9 inhibitors,” said Dr. David Maron, a preventive cardiologist at Stanford University.

In a 24‑week Phase III trial disclosed last November, Merck enrolled 2,912 participants receiving Lipfendra; the therapy achieved LDL reductions of up to 60 % and exhibited a safety profile comparable to placebo.

The efficacy profile mirrors that of the existing injectable PCSK9 inhibitors.

Existing injectable PCSK9 inhibitor trials demonstrated a 20 % reduction in major adverse cardiovascular events—heart attacks, strokes and cardiovascular deaths—in high‑risk populations. Merck is now running an outcomes study to confirm that Lipfendra provides a comparable clinical benefit, and Dr. Dean Li, president of Merck Research Laboratories, expressed confidence that it will.

Dr. Li emphasized Merck’s goal of making cholesterol reduction “as simple and convenient as taking a statin,” noting that Lipfendra can be prescribed by primary‑care physicians without restriction to cardiologists. He added that patients are already accustomed to daily oral therapy and that most high‑risk individuals already manage multiple preventive medications, including antihypertensives, statins and aspirin.

It remains uncertain whether makers of existing injectable PCSK9 inhibitors will adjust their pricing in response to the new oral option.

Source link